Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, Apatinib, Oxaliplatin, and S-1 Neoadjuvant Therapy for Advanced Gastric Cancer
NCT05223088Phase 2Completed
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric cancer (GC), sponsored by Fujian Medical University Cancer Hospital. Started Oct 2021; status: completed.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05223088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223088.